FDA and BPC-157: Understanding the "Category 2" Classification

In 2023, the U.S. Food and Drug Administration (FDA) made an important decision regarding BPC-157 by classifying it as a "Category 2 bulk drug substance."

WHAT DOES "CATEGORY 2" MEAN?

This classification indicates that:

1. BPC-157 CANNOT be prepared by commercial compounding pharmacies
2. There is insufficient evidence to determine whether it could cause harm in humans
3. The peptide is not approved as a drug

WHAT REMAINS LEGAL

Despite this classification, many BPC-157 products are legally sold as:

• "Research chemicals"
• "Dietary supplements"

These categories are not subject to the same regulations as drugs.

SITUATION IN THE UK

In the UK, the MHRA (Medicines and Healthcare products Regulatory Agency) maintains a strict position: these peptides are only authorized for research purposes, within approved studies.

PRACTICAL IMPLICATIONS

For researchers: BPC-157 remains accessible for in vitro and preclinical research.

For suppliers: sale is possible subject to clear labeling "for research purposes only."

For consumers: caution is advised. Lack of approval means lack of guarantees on safety and efficacy.